Give Online: Help shape patient care for generations to come.
Cleveland Clinic Logo

Appointments

Request an Appointment

Cancer Answer Line:
866.223.8100

M-F 8 a.m. - 4:30 p.m. ET

Expand Content

Cancer Clinical Trials Results

IRBCCTitleHospitalStagePhaseDisease
3952  Collection of Blood and Bone Marrow from Allogeneic Hematopoietic Cell Transplant Recipients and their Related Donors Main Campus  Aplastic Anemia, Bone Cancer, Bone Marrow Failure, Leukemia, Acute Lymphoblastic (ALL) , Leukemia, Acute Myeloid (AML), Leukemia, Chronic Lymphocytic (CLL), Leukemia, Chronic Myeloid (CML), Lymphoma, Lymphoma, Hodgkin, Lymphoma, Non - Hodgkin, Multiple Myeloma, Myelodysplastic Syndrome (MDS)
BIP 1914 14-1163 A Phase I/II, Multicenter, Open-label, Dose Escalation and Randomized Trial of BI 836858 in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes Main Campus Phase 1, Phase 2Myelodysplastic Syndrome (MDS)
CLGN 2915 16-462 A Phase 3, Double-Blind, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Placebo For the Treatment of Anemia Due to IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndromes in Subjects With Ring Sideroblasts Who Require Red Blood Cell Transfusions Main Campus Phase 3Myelodysplastic Syndrome (MDS)
CTN 110214-886 A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplant to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Intermediate-2 and High Risk Myelodysplastic Syndrome Main Campus  Myelodysplastic Syndrome (MDS)
DFCI 191414-1480 Interventional Validation of an MDS-Specific Measure of Quality of Life: Assessing the Responsiveness of the QUALMS-1 to Different Hypomethylating Agent Regimens for Low and Intermediate Risk Disease Fairview, Hillcrest, Independence, Main Campus, Mansfield, North Coast Cancer, South Pointe, Strongsville, Wooster Phase 2Myelodysplastic Syndrome (MDS)
FHCC 1915 15-499 Initial cytoreductive therapy for myelodysplastic syndrome prior to allogeneic hematopoietic cell transplantation (the ICT-HCT Study). Main Campus  Myelodysplastic Syndrome (MDS)
FHCRC 191314-207 Feasibility and Outcomes of Allogeneic Hematopoietic Cell Transplantation (HCT) Compared to Conventional Therapy for Older and Medically Infirm Patients Diagnosed with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes: A Prospective Observational Study Main Campus Phase 4Leukemia, Acute Myeloid (AML), Myelodysplastic Syndrome (MDS)
MDCC 191414-1479 Phase II Randomized Study of Lower Doses of Decitabine (DAC; 20mg/m2 IV daily for 3 days every month) versus Azacitidine (AZA; 75 mg/m2 SC/IV daily for 3 days every month) versus Azacitidine (AZA; 75 mg/m2 SC/IV daily for 5 days every month) in MDS Patients with Low and Intermediate-1 Risk Disease Transfusion-Dependent versus Best Supportive Care (BSC) in MDS Patients with Low and Intermediate-1 Risk Disease Transfusion-Independent Fairview, Hillcrest, Independence, Main Campus, Mansfield, North Coast Cancer, South Pointe, Strongsville, Wooster Phase 2Myelodysplastic Syndrome (MDS)
MLNM 1915 16-190 A Phase 2, Randomized, Controlled, Open-Label, Clinical Study of the Efficacy and Safety of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Low-Blast Acute Myelogenous Leukemia Main Campus Phase 2Leukemia, Acute Myeloid (AML), Leukemia, Chronic Myelomonocytic (CMML), Myelodysplastic Syndrome (MDS)
NHLBI-MDS 16-817 Randomized Phase II Study of Cisplatin and Etoposide versus Temozolomide and Capecitabine in Patients with Advanced G3 Non-Small Cell Gastroenteropancreatic Neuroendocrine Carcinomas Main CampusAdvanced/MetsPhase 2GI (Gastrointestinal), Myelodysplastic Syndrome (MDS), Pancreas
ROCH 1915 15-767 A PHASE IB STUDY OF THE SAFETY AND PHARMACOLOGY OF MPDL3280A (ANTI-PD-L1 ANTIBODY) ADMINISTERED ALONE OR IN COMBINATION WITH AZACITIDINE IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES Main Campus Phase 1Myelodysplastic Syndrome (MDS)

Cancer Answers & Appointments

Speak with a cancer nurse specialist for appointment assistance and for answers to your questions about cancer locally at 216.444.7923 or toll-free 1.866.223.8100.

Monday through Friday from 8 a.m. – 4:30 p.m. (ET).

Referrals

Resources for medical professionals

  • Outpatient appointment referrals: 216.444.7923 or 866.223.8100
  • Inpatient hospital transfers: 800.553.5056
  • Referring Physician Concierge: 216.444.6196 or 216.312.4910.

Clinical Trials

Search available cancer clinical trials by disease, hospital, phase or number.